Literature DB >> 31345630

The Changing Clinical Spectrum of Hypophysitis.

Sabrina Chiloiro1, Ettore Domenico Capoluongo2, Tommaso Tartaglione3, Antonella Giampietro1, Antonio Bianchi1, Andrea Giustina4, Alfredo Pontecorvi1, Laura De Marinis5.   

Abstract

Hypophysitis is a rare and potentially life-threatening disease, characterized by an elevated risk of complications, such as occurrence of acute central hypoadrenalism, persistent hypopituitarism, or extension of the inflammatory process to the neighboring neurological structures. In recent years, a large number of patients have been described as being affected by hypophysitis, due to the increased administration of immuno-chemotherapies. At the present time, the heterogeneous nature of hypophysitis diagnostic criteria and of the treatment protocols makes the management of affected patients difficult. We review the current data and evidence on primary and secondary hypophysitis, in order to suggest a diagnostic and therapeutic protocol that should be focused on a multidisciplinary approach, for reaching a prompt diagnosis and an appropriate and safe treatment.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  autoimmune; diabetes insipidus; hypopituitarism; immunotherapy; ipilimumab; pituitary

Year:  2019        PMID: 31345630     DOI: 10.1016/j.tem.2019.06.004

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  9 in total

Review 1.  Hypophysitis: An update on the novel forms, diagnosis and management of disorders of pituitary inflammation.

Authors:  Sriram Gubbi; Fady Hannah-Shmouni; Joseph G Verbalis; Christian A Koch
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2019-12-12       Impact factor: 4.690

2.  COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology.

Authors:  M Puig-Domingo; M Marazuela; B O Yildiz; A Giustina
Journal:  Endocrine       Date:  2021-05-08       Impact factor: 3.633

3.  Markers of humoral and cell-mediated immune response in primary autoimmune hypophysitis: a pilot study.

Authors:  Sabrina Chiloiro; Antonella Giampietro; Flavia Angelini; Vincenzo Arena; Egidio Stigliano; Tommaso Tartaglione; Pier Paolo Mattogno; Quintino Giorgio D'Alessandris; Liverana Lauretti; Alfredo Pontecorvi; Laura De Marinis; Antonio Bianchi
Journal:  Endocrine       Date:  2021-01-23       Impact factor: 3.633

Review 4.  Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment.

Authors:  Giulia Di Dalmazi; Silvia Ippolito; Isabella Lupi; Patrizio Caturegli
Journal:  Expert Rev Endocrinol Metab       Date:  2019-11

Review 5.  COVID-19 and the pituitary.

Authors:  Stefano Frara; Agnese Allora; Laura Castellino; Luigi di Filippo; Paola Loli; Andrea Giustina
Journal:  Pituitary       Date:  2021-05-03       Impact factor: 3.599

6.  Recurrent autoimmune hypophysitis treated with rituximab: a case report.

Authors:  Maria Kruse; Thomas Bastholm Olesen; Ljubo Markovic; Dorte Glintborg; Marianne Skovsager Andersen
Journal:  J Med Case Rep       Date:  2021-12-15

7.  Central adrenal insufficiency and diabetes insipidus as potential endocrine manifestations of COVID-19 infection: a case report.

Authors:  Abu Baker Sheikh; Muhammad Ali Javaid; Abdul Ahad Ehsan Sheikh; Rahul Shekhar
Journal:  Pan Afr Med J       Date:  2021-02-26

Review 8.  Endocrine and metabolic aspects of the COVID-19 pandemic.

Authors:  Mónica Marazuela; Andrea Giustina; Manuel Puig-Domingo
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

Review 9.  Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction.

Authors:  Lian Duan; Linjie Wang; Hanping Wang; Xiaoyan Si; Li Zhang; Xiaowei Liu; Yue Li; Xiaoxiao Guo; Jiaxin Zhou; Huijuan Zhu; Li Zhang
Journal:  Thorac Cancer       Date:  2020-02-11       Impact factor: 3.500

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.